AdvaMed investigates "device lag": AdvaMed is studying the phenomenon of "device lag", whereby new medical technologies are often first available outside of the United States, and has engaged consulting firm PricewaterhouseCoopers to do a comprehensive review of the issue, AdvaMed CEO Stephen Ubl announced during a Feb. 24 media briefing on policy priorities. New devices are commonly available first in Europe, Ubl noted, "and surely we should be asking the question whether that is appropriate and whether we can do a better job with respect to some technologies making sure they're available in the U.S. first." The review, which is due in May, will examine "certain data elements" in nine countries, including regulatory review timelines and investment levels, "to try to get a better handle on whether this device lag occurs and [identify] potential solutions," Ubl said. "Candidly, the interest is in stimulating a race to the top, to be able to visit with ... government leaders across markets [with] a valid, objective measurement of how well various components of their system are doing in the service of patient access to medical technology." The study comes as FDA evaluates potential changes to its 510(k) program with an eye toward improving device safety, which could slow market access (1"The Gray Sheet" Feb. 22, 2010)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.